Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)

B.O. Khatri, J. Pelletier, L. Kappos, H.P. Hartung, G. Comi, F. Barkhof, P. von Rosenstiel, X. Meng, A. Grinspan, R. Hashmonay, J.A. Cohen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)355-363
JournalMultiple Sclerosis and Related Disorders
Volume3
Issue number3
DOIs
Publication statusPublished - 2014

Cite this

@article{c9fbc3f2e800488fb22ca996148e7639,
title = "Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)",
author = "B.O. Khatri and J. Pelletier and L. Kappos and H.P. Hartung and G. Comi and F. Barkhof and {von Rosenstiel}, P. and X. Meng and A. Grinspan and R. Hashmonay and J.A. Cohen",
year = "2014",
doi = "10.1016/j.msard.2013.11.006",
language = "English",
volume = "3",
pages = "355--363",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",
number = "3",

}

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS). / Khatri, B.O.; Pelletier, J.; Kappos, L.; Hartung, H.P.; Comi, G.; Barkhof, F.; von Rosenstiel, P.; Meng, X.; Grinspan, A.; Hashmonay, R.; Cohen, J.A.

In: Multiple Sclerosis and Related Disorders, Vol. 3, No. 3, 2014, p. 355-363.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)

AU - Khatri, B.O.

AU - Pelletier, J.

AU - Kappos, L.

AU - Hartung, H.P.

AU - Comi, G.

AU - Barkhof, F.

AU - von Rosenstiel, P.

AU - Meng, X.

AU - Grinspan, A.

AU - Hashmonay, R.

AU - Cohen, J.A.

PY - 2014

Y1 - 2014

U2 - 10.1016/j.msard.2013.11.006

DO - 10.1016/j.msard.2013.11.006

M3 - Article

VL - 3

SP - 355

EP - 363

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

IS - 3

ER -